Navigation Links
Nektar Therapeutics' President and CEO Howard W. Robin to Present At JPMorgan 26th Annual Healthcare Conference
Date:1/3/2008

SAN CARLOS, Calif., Jan. 2 /PRNewswire-FirstCall/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and CEO Howard W. Robin will deliver the corporate presentation at the upcoming JPMorgan 26th Annual Healthcare Conference at the Westin St. Francis Hotel in San Francisco, California on Tuesday, January 8, 2008, at 4:30 p.m. Pacific Time.

The presentation will be accessible through a live audio and slideshow webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website: http://www.nektar.com. This Webcast will be available for replay until January 22, 2008.

Nektar Therapeutics is a biopharmaceutical company that develops and enables differentiated therapeutics with its industry-leading PEGylation and pulmonary drug development platforms. Nektar PEGylation and pulmonary technology, expertise, and manufacturing capabilities have enabled ten approved products for partners, which include the world's leading pharmaceutical and biotechnology companies. Nektar also develops its own products by applying its PEGylation and pulmonary technology platforms to existing medicines with the objective to enhance performance, such as improving efficacy, safety and compliance.

Nektar Therapeutics

201 Industrial Road

San Carlos, CA 94070

650-631-3100 Phone 650-631-3150 Fax


'/>"/>
SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
2. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
3. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
4. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
5. Nektar Therapeutics President and CEO Howard Robin to Present at 2007 BIO InvestorForum
6. Nektar Therapeutics to Present at 2007 BMO Capital Markets Focus on Healthcare Conference
7. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
9. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
10. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
11. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 2014 Rancho BioSciences , the ... manually curated public data source TCGA for ... the data is now available for other oncology groups. ... and internal data sources for their Pharma, Government and ... the data that becomes more easily accessible. Rancho ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 Whitehouse Laboratories ... its ICH Stability Testing and Package Test Capacity. Responding ... centers on a dramatic increase in environmental chamber storage ... stability, storage and aging samples to be securely held ... this major capital expenditure has already taken place with ...
(Date:10/30/2014)... Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ), ... present a company overview at the Nomura Biotechnology Conference on ... Boston, MA. A live webcast ... Media" section of the Company,s website, www.isispharm.com .  A ... hours and will be archived for a limited time. ...
(Date:10/30/2014)... challenges in the development of quantum technologies has been ... paper published today (28 October) in Nature Communications ... make a new type of flexibly designed microscopic trap ... sensors and specialised superfast computers, often depend on harnessing ... trapping these tiny particles are hugely problematic because of ...
Breaking Biology Technology:Rancho BioSciences Manually Curated TCGA Data Sets Available 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2
... Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) and ... announced that a supplemental New Drug Application (sNDA) has been ... the expanded use of BYETTA® (exenatide) injection as an add-on ... thiazolidinedione (TZD) in conjunction with diet and exercise for adults ...
... 22, 2010 Novavax, Inc. (Nasdaq: NVAX ... School, led by Dr. Trudy Morrison, published in the ... report indicating that a novel virus-like particle (VLP) vaccine ... a live virus challenge.  This vaccine candidate has been ...
... the University of Santiago de Compostela (USC) have analysed levels ... in Galicia. The results show that 34% of these schools ... Union. Excessive inhalation of radon is associated with lung cancer. ... taken, 34% had radon levels in excess of 400 Bequerels/m3 ...
Cached Biology Technology:Amylin and Lilly Seek Expanded Use of BYETTA® Along with Basal Insulin 2Amylin and Lilly Seek Expanded Use of BYETTA® Along with Basal Insulin 3Amylin and Lilly Seek Expanded Use of BYETTA® Along with Basal Insulin 4Amylin and Lilly Seek Expanded Use of BYETTA® Along with Basal Insulin 5Amylin and Lilly Seek Expanded Use of BYETTA® Along with Basal Insulin 6Amylin and Lilly Seek Expanded Use of BYETTA® Along with Basal Insulin 7NOVAVAX and University of Massachusetts Medical School Publish Preclinical Safety and Efficacy Study of a Respiratory Syncytial Virus (RSV) Virus-like Particle (VLP) Vaccine Candidate 2NOVAVAX and University of Massachusetts Medical School Publish Preclinical Safety and Efficacy Study of a Respiratory Syncytial Virus (RSV) Virus-like Particle (VLP) Vaccine Candidate 3NOVAVAX and University of Massachusetts Medical School Publish Preclinical Safety and Efficacy Study of a Respiratory Syncytial Virus (RSV) Virus-like Particle (VLP) Vaccine Candidate 434 percent of Galician secondary schools exceed maximum recommended radon levels 2
(Date:10/30/2014)... 2014 Biological membranes are mainly composed of lipid ... solution ions onto lipid membranes helps clarify functional ... provides a quantitative description of the equilibria between ... and Zbigniew Figaszewski from the University of Bialystok, ... these findings, just published in EPJ E ...
(Date:10/29/2014)... released by unconventional oil and gas production are well ... in the open access journal Environmental Health . ... found. The study is the first to be based ... sites and could be used to supplement official air-quality ... reserves that do not readily flow to the surface. ...
(Date:10/29/2014)... In the largest study of its kind to date, ... genes that heighten the risk for autism. Joseph Buxbaum, ... York City, Mark Daly, Ph.D., Broad Institute of Harvard ... DNA samples from affected children, parents and unrelated people. ... to contribute to the risk for autism spectrum disorder ...
Breaking Biology News(10 mins):Ion adsorption matter in biology 2Air quality and unconventional oil and gas sites 2Air quality and unconventional oil and gas sites 3
... BiOptix announced continued support of the Colorado BioScience ... life sciences showcase event in Colorado to be ... continues to believe in the goals and community that is ... President and CEO of BiOptix.   "As Colorado continues to ...
... become more severe in the Southwest, trees are increasingly ... to middle elevations, University of Arizona researchers report in ... Journal of Geophysical Research Biogeosciences ., Lead author Jeremy ... of geosciences, said: "We know the climate in the ...
... study provides a first-time analysis of the value of forage ... and anchovies. Three kinds of contributions of forage fish were ... fish, and as an important link in the food web ... a total of $16.9 billion, as both direct catch and ...
Cached Biology News:BiOptix Participates in Leading Life Sciences Event BioWest 2012 2Droughts are pushing trees to the limit 2Droughts are pushing trees to the limit 3Droughts are pushing trees to the limit 4Study provides first-time analysis of 3 distinct contributions of forage fish worldwide 2Study provides first-time analysis of 3 distinct contributions of forage fish worldwide 3
... compact benchtop and stackable multi-function incubator. ... a large display screen to accurately ... circulation inside to evenly distribute temperature ... easily calibrated from the microprocessor controller. ...
... --- a cocktail of 3 siRNAs specifically ... our most popular product. The siTrio reagent ... of your target gene when used under ... and confirmation of optimal transfection with one ...
... with 96 x 0.2 ml reaction module ... applications. It is equipped with an interchangeable ... is compatible with optical modules for real-time ... by algorithm, block, or in-sample probe. It ...
... compact benchtop and stackable multi-function incubator. ... a large display screen to accurately ... circulation inside to evenly distribute temperature ... easily calibrated from the microprocessor controller. ...
Biology Products: